View Financial HealthNRGene Technologies 배당 및 자사주 매입배당 기준 점검 0/6NRGene Technologies 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesReported Earnings • Mar 31Full year 2025 earnings released: US$0.12 loss per share (vs US$0.27 loss in FY 2024)Full year 2025 results: US$0.12 loss per share (improved from US$0.27 loss in FY 2024). Revenue: US$3.17m (up 146% from FY 2024). Net loss: US$1.50m (loss narrowed 55% from FY 2024). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.New Risk • Mar 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.0m free cash flow). Share price has been highly volatile over the past 3 months (8.6% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (US$1.2m revenue). Market cap is less than US$100m (₪39.5m market cap, or US$12.8m).New Risk • Dec 21New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₪31.7m (US$9.88m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.0m free cash flow). Share price has been highly volatile over the past 3 months (7.8% average weekly change). Market cap is less than US$10m (₪31.7m market cap, or US$9.88m). Minor Risk Revenue is less than US$5m (US$1.2m revenue).New Risk • Aug 21New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₪32.8m (US$9.63m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.2m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Market cap is less than US$10m (₪32.8m market cap, or US$9.63m). Minor Risk Revenue is less than US$5m (US$1.3m revenue).공지 • May 16NRGene Technologies Ltd, Annual General Meeting, Jun 18, 2025NRGene Technologies Ltd, Annual General Meeting, Jun 18, 2025. Location: company offices, IsraelNew Risk • Apr 05New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₪37.1m (US$9.90m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.2m free cash flow). Earnings have declined by 1.7% per year over the past 5 years. Market cap is less than US$10m (₪37.1m market cap, or US$9.90m). Minor Risk Revenue is less than US$5m (US$1.3m revenue).Reported Earnings • Mar 28Full year 2024 earnings released: US$0.27 loss per share (vs US$0.42 loss in FY 2023)Full year 2024 results: US$0.27 loss per share (improved from US$0.42 loss in FY 2023). Revenue: US$1.29m (down 36% from FY 2023). Net loss: US$3.36m (loss narrowed 36% from FY 2023). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.New Risk • Mar 09New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.9m free cash flow). Earnings have declined by 6.6% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (8.0% average weekly change). Revenue is less than US$5m (US$1.6m revenue). Market cap is less than US$100m (₪39.7m market cap, or US$11.0m).New Risk • Dec 15New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₪35.1m (US$9.74m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.9m free cash flow). Earnings have declined by 6.6% per year over the past 5 years. Market cap is less than US$10m (₪35.1m market cap, or US$9.74m). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Revenue is less than US$5m (US$1.6m revenue).New Risk • Dec 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 7.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.9m free cash flow). Share price has been highly volatile over the past 3 months (7.4% average weekly change). Earnings have declined by 6.6% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Revenue is less than US$5m (US$1.6m revenue). Market cap is less than US$100m (₪49.4m market cap, or US$13.6m).New Risk • Aug 24New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$5.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.9m free cash flow). Earnings have declined by 6.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (3.0% increase in shares outstanding). Revenue is less than US$5m (US$1.6m revenue). Market cap is less than US$100m (₪44.8m market cap, or US$12.2m).공지 • Aug 15NRGene Technologies Ltd to Report Q2, 2024 Results on Aug 20, 2024NRGene Technologies Ltd announced that they will report Q2, 2024 results on Aug 20, 2024New Risk • Aug 05New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 10% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Shareholders have been diluted in the past year (3.0% increase in shares outstanding). Revenue is less than US$5m (US$2.0m revenue). Market cap is less than US$100m (₪48.6m market cap, or US$12.7m).공지 • Mar 27NRGene Technologies Ltd, Annual General Meeting, Apr 30, 2024NRGene Technologies Ltd, Annual General Meeting, Apr 30, 2024, at 14:00 Israel Standard Time.공지 • Mar 20NRGene Technologies Ltd to Report Q4, 2023 Results on Mar 20, 2024NRGene Technologies Ltd announced that they will report Q4, 2023 results on Mar 20, 2024New Risk • Mar 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 15% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (US$2.8m revenue). Market cap is less than US$100m (₪42.6m market cap, or US$11.7m).New Risk • Jan 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.5% average weekly change). Earnings have declined by 15% per year over the past 5 years. Minor Risks Revenue is less than US$5m (US$2.8m revenue). Market cap is less than US$100m (₪37.7m market cap, or US$10.1m).New Risk • Jul 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 22% per year over the past 5 years. Market cap is less than US$10m (₪29.6m market cap, or US$7.96m). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Revenue is less than US$5m (US$3.2m revenue).Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 8 non-independent directors. Independent External Director Oren Mohar was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.공지 • Aug 17NRGene Technologies Ltd to Report Q2, 2022 Results on Aug 15, 2022NRGene Technologies Ltd announced that they will report Q2, 2022 results on Aug 15, 2022Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Director Leah Karmel Goren was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 03Full year 2021 earnings released: US$0.69 loss per share (vs US$0.36 loss in FY 2020)Full year 2021 results: US$0.69 loss per share (down from US$0.36 loss in FY 2020). Revenue: US$4.46m (down 37% from FY 2020). Net loss: US$8.34m (loss widened 165% from FY 2020).공지 • Feb 03NRGene and Philoseed Reach Major Milestone Towards Developing ToBRFV High Resistance Tomato VarietiesNRGene and Philoseed announced a major milestone in the development of high resistant tomato varieties to overcome the tomato brown rugose fruit virus – ToBRFV. This advance encompasses the discovery of a unique region in the tomato genome, essential to the tomatoes’ resistance to the virus. The companies are in the process of patent protection of this previously unreported genomic region. The highly contagious tomato virus has been spreading rapidly in Europe, Asia, Africa, and in parts of Mexico and the US, threatening the tomato industry worldwide. This discovery of a unique tomato genomic region is another step forward towards complete resistance solution. It will facilitate the development of DNA markers and seeds of ToBRFV high resistance (HR) tomato varieties and is expected to be completed by the end of 2022. NRGene is currently offering immediate access to the discovered genomic region and DNA markers, and has already signed several commercial contracts, commercializing ToBRFV HR trait with Israeli, European and US companies.공지 • Mar 04Nrgene Announces Successful Completion and Results of the Canola/Rapeseed Pan-GenomeNRGene announced the successful completion and results of the canola/rapeseed pan-genome. The International Canola Pan-genome Consortium was established in 2019 to advance the rapeseed agricultural industry by capturing this crop's broad genetic diversity. The global consortium was led jointly by Dr. Isobel Parkin from the Government of Canada’s Agriculture & Agri-food Canada (AAFC), Dr. Andrew Sharpe from the Global Institute for Food Security (GIFS) at the University of Saskatchewan, Canada, and NRGene. The consortium included key players in the canola industry, among them Bayer, Corteva Agriscience, Nutrien Ag Solutions and Nuseed. Each contributed their own canola lines to the research and received the full pangenome comparison results. Rapeseed is a major oil seed crop considered to be a high-quality vegetable oil and commonly used in food production and various industrial applications, including biofuel. According to the United Nation’s Food and Agriculture Organization, rapeseed is farmed on approximately 35 million acres globally and produced 85 million tons in 2019. Canola is the brand name for Canadian rapeseed varieties. Extensive breeding is done globally, focusing on developing higher yielding and more nutritional rapeseed varieties that can naturally resist plant diseases. The use of DNA markers already enhanced canola breeding over the past three decades. Yet, due to canola’s genome complexity, diversity, and instability, the need for a whole genome understanding became a bottleneck in canola breeding. Building a pan-genome database to unravel the broad genomic diversity in canola is the key to expanding the crop’s productivity.공지 • Feb 23NRGene and Kayagene Announces Exclusive Agreement for Commercialization of the Autoflower Trait of CannabisNRGene and Kayagene signed an agreement that grants NRGene a world-wide, exclusive license to commercialize the Cannabis autoflower trait and DNA markers linked to it. Utilizing NRGene’s proprietary genomic tools and Kayagene’s proprietary germplasm and breeding knowledge the two companies recently identified the markers associated with the trait. The DNA markers will enable breeders to develop elite autoflower varieties quicker and more efficiently than before. NRGene will offer to license the autoflower trait and linked DNA markers to breeders and growers around the world, while Kayagene will be responsible for delivery of the seeds and pollen harboring the trait.공지 • Feb 11NRgene and Kayagene Announces the Completion of Milestone in Their Strategic Research CollaborationNRGene and Kayagene announced the completion of a milestone in their strategic research collaboration. This ongoing collaboration was initiated over 2 years ago, beginning with genomic assembly of several of Kayagene’s cannabis and hemp breeding lines, using NRGene’s DenovoMAGIC™ technology. Now, the companies have successfully mapped several key genes including the autoflowering gene, which is a highly desired trait and of great interest for the hemp and cannabis industries. NRGene estimates, that following the development of DNA markers for the autoflowering trait, it is now possible to integrate this trait into any hemp and cannabis variety within 12 to 18 months. Trait mapping and marker-assisted breeding are vital in a competitive market because it accelerates the time to market for unique and improved varieties harboring those key traits. The use of molecular markers enables rapid and accurate selections and reduces the presence of deleterious genes introduced by traditional breeding methods.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 NRGN 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: NRGN 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장NRGene Technologies 배당 수익률 vs 시장NRGN의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (NRGN)n/a시장 하위 25% (IL)1.7%시장 상위 25% (IL)5.1%업계 평균 (Software)1.0%분석가 예측 (NRGN) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 NRGN 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 NRGN 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 NRGN 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: NRGN 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YIL 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/10 17:05종가2026/05/07 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스NRGene Technologies Ltd는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Mar 31Full year 2025 earnings released: US$0.12 loss per share (vs US$0.27 loss in FY 2024)Full year 2025 results: US$0.12 loss per share (improved from US$0.27 loss in FY 2024). Revenue: US$3.17m (up 146% from FY 2024). Net loss: US$1.50m (loss narrowed 55% from FY 2024). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
New Risk • Mar 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.0m free cash flow). Share price has been highly volatile over the past 3 months (8.6% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (US$1.2m revenue). Market cap is less than US$100m (₪39.5m market cap, or US$12.8m).
New Risk • Dec 21New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₪31.7m (US$9.88m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.0m free cash flow). Share price has been highly volatile over the past 3 months (7.8% average weekly change). Market cap is less than US$10m (₪31.7m market cap, or US$9.88m). Minor Risk Revenue is less than US$5m (US$1.2m revenue).
New Risk • Aug 21New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₪32.8m (US$9.63m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.2m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Market cap is less than US$10m (₪32.8m market cap, or US$9.63m). Minor Risk Revenue is less than US$5m (US$1.3m revenue).
공지 • May 16NRGene Technologies Ltd, Annual General Meeting, Jun 18, 2025NRGene Technologies Ltd, Annual General Meeting, Jun 18, 2025. Location: company offices, Israel
New Risk • Apr 05New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₪37.1m (US$9.90m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.2m free cash flow). Earnings have declined by 1.7% per year over the past 5 years. Market cap is less than US$10m (₪37.1m market cap, or US$9.90m). Minor Risk Revenue is less than US$5m (US$1.3m revenue).
Reported Earnings • Mar 28Full year 2024 earnings released: US$0.27 loss per share (vs US$0.42 loss in FY 2023)Full year 2024 results: US$0.27 loss per share (improved from US$0.42 loss in FY 2023). Revenue: US$1.29m (down 36% from FY 2023). Net loss: US$3.36m (loss narrowed 36% from FY 2023). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
New Risk • Mar 09New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.9m free cash flow). Earnings have declined by 6.6% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (8.0% average weekly change). Revenue is less than US$5m (US$1.6m revenue). Market cap is less than US$100m (₪39.7m market cap, or US$11.0m).
New Risk • Dec 15New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₪35.1m (US$9.74m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.9m free cash flow). Earnings have declined by 6.6% per year over the past 5 years. Market cap is less than US$10m (₪35.1m market cap, or US$9.74m). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Revenue is less than US$5m (US$1.6m revenue).
New Risk • Dec 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 7.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.9m free cash flow). Share price has been highly volatile over the past 3 months (7.4% average weekly change). Earnings have declined by 6.6% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Revenue is less than US$5m (US$1.6m revenue). Market cap is less than US$100m (₪49.4m market cap, or US$13.6m).
New Risk • Aug 24New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$5.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.9m free cash flow). Earnings have declined by 6.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (3.0% increase in shares outstanding). Revenue is less than US$5m (US$1.6m revenue). Market cap is less than US$100m (₪44.8m market cap, or US$12.2m).
공지 • Aug 15NRGene Technologies Ltd to Report Q2, 2024 Results on Aug 20, 2024NRGene Technologies Ltd announced that they will report Q2, 2024 results on Aug 20, 2024
New Risk • Aug 05New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 10% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Shareholders have been diluted in the past year (3.0% increase in shares outstanding). Revenue is less than US$5m (US$2.0m revenue). Market cap is less than US$100m (₪48.6m market cap, or US$12.7m).
공지 • Mar 27NRGene Technologies Ltd, Annual General Meeting, Apr 30, 2024NRGene Technologies Ltd, Annual General Meeting, Apr 30, 2024, at 14:00 Israel Standard Time.
공지 • Mar 20NRGene Technologies Ltd to Report Q4, 2023 Results on Mar 20, 2024NRGene Technologies Ltd announced that they will report Q4, 2023 results on Mar 20, 2024
New Risk • Mar 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 15% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (US$2.8m revenue). Market cap is less than US$100m (₪42.6m market cap, or US$11.7m).
New Risk • Jan 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.5% average weekly change). Earnings have declined by 15% per year over the past 5 years. Minor Risks Revenue is less than US$5m (US$2.8m revenue). Market cap is less than US$100m (₪37.7m market cap, or US$10.1m).
New Risk • Jul 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 22% per year over the past 5 years. Market cap is less than US$10m (₪29.6m market cap, or US$7.96m). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Revenue is less than US$5m (US$3.2m revenue).
Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 8 non-independent directors. Independent External Director Oren Mohar was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
공지 • Aug 17NRGene Technologies Ltd to Report Q2, 2022 Results on Aug 15, 2022NRGene Technologies Ltd announced that they will report Q2, 2022 results on Aug 15, 2022
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Director Leah Karmel Goren was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 03Full year 2021 earnings released: US$0.69 loss per share (vs US$0.36 loss in FY 2020)Full year 2021 results: US$0.69 loss per share (down from US$0.36 loss in FY 2020). Revenue: US$4.46m (down 37% from FY 2020). Net loss: US$8.34m (loss widened 165% from FY 2020).
공지 • Feb 03NRGene and Philoseed Reach Major Milestone Towards Developing ToBRFV High Resistance Tomato VarietiesNRGene and Philoseed announced a major milestone in the development of high resistant tomato varieties to overcome the tomato brown rugose fruit virus – ToBRFV. This advance encompasses the discovery of a unique region in the tomato genome, essential to the tomatoes’ resistance to the virus. The companies are in the process of patent protection of this previously unreported genomic region. The highly contagious tomato virus has been spreading rapidly in Europe, Asia, Africa, and in parts of Mexico and the US, threatening the tomato industry worldwide. This discovery of a unique tomato genomic region is another step forward towards complete resistance solution. It will facilitate the development of DNA markers and seeds of ToBRFV high resistance (HR) tomato varieties and is expected to be completed by the end of 2022. NRGene is currently offering immediate access to the discovered genomic region and DNA markers, and has already signed several commercial contracts, commercializing ToBRFV HR trait with Israeli, European and US companies.
공지 • Mar 04Nrgene Announces Successful Completion and Results of the Canola/Rapeseed Pan-GenomeNRGene announced the successful completion and results of the canola/rapeseed pan-genome. The International Canola Pan-genome Consortium was established in 2019 to advance the rapeseed agricultural industry by capturing this crop's broad genetic diversity. The global consortium was led jointly by Dr. Isobel Parkin from the Government of Canada’s Agriculture & Agri-food Canada (AAFC), Dr. Andrew Sharpe from the Global Institute for Food Security (GIFS) at the University of Saskatchewan, Canada, and NRGene. The consortium included key players in the canola industry, among them Bayer, Corteva Agriscience, Nutrien Ag Solutions and Nuseed. Each contributed their own canola lines to the research and received the full pangenome comparison results. Rapeseed is a major oil seed crop considered to be a high-quality vegetable oil and commonly used in food production and various industrial applications, including biofuel. According to the United Nation’s Food and Agriculture Organization, rapeseed is farmed on approximately 35 million acres globally and produced 85 million tons in 2019. Canola is the brand name for Canadian rapeseed varieties. Extensive breeding is done globally, focusing on developing higher yielding and more nutritional rapeseed varieties that can naturally resist plant diseases. The use of DNA markers already enhanced canola breeding over the past three decades. Yet, due to canola’s genome complexity, diversity, and instability, the need for a whole genome understanding became a bottleneck in canola breeding. Building a pan-genome database to unravel the broad genomic diversity in canola is the key to expanding the crop’s productivity.
공지 • Feb 23NRGene and Kayagene Announces Exclusive Agreement for Commercialization of the Autoflower Trait of CannabisNRGene and Kayagene signed an agreement that grants NRGene a world-wide, exclusive license to commercialize the Cannabis autoflower trait and DNA markers linked to it. Utilizing NRGene’s proprietary genomic tools and Kayagene’s proprietary germplasm and breeding knowledge the two companies recently identified the markers associated with the trait. The DNA markers will enable breeders to develop elite autoflower varieties quicker and more efficiently than before. NRGene will offer to license the autoflower trait and linked DNA markers to breeders and growers around the world, while Kayagene will be responsible for delivery of the seeds and pollen harboring the trait.
공지 • Feb 11NRgene and Kayagene Announces the Completion of Milestone in Their Strategic Research CollaborationNRGene and Kayagene announced the completion of a milestone in their strategic research collaboration. This ongoing collaboration was initiated over 2 years ago, beginning with genomic assembly of several of Kayagene’s cannabis and hemp breeding lines, using NRGene’s DenovoMAGIC™ technology. Now, the companies have successfully mapped several key genes including the autoflowering gene, which is a highly desired trait and of great interest for the hemp and cannabis industries. NRGene estimates, that following the development of DNA markers for the autoflowering trait, it is now possible to integrate this trait into any hemp and cannabis variety within 12 to 18 months. Trait mapping and marker-assisted breeding are vital in a competitive market because it accelerates the time to market for unique and improved varieties harboring those key traits. The use of molecular markers enables rapid and accurate selections and reduces the presence of deleterious genes introduced by traditional breeding methods.